Pedro Hernandez-Rios, MD
Internal Medicine · Pembroke Pines, FLNPI 1568497485
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $99 and has fallen 64.0% since, to $36 in 2025. That places this record below the midpoint for internal medicine clinicians in FL, where the typical reported total is $316.
Across 14 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$71
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$68
- Lilly USA, LLC$36
- Johnson & Johnson$28
- Ultragenyx Pharmaceutical Inc.$28
- Takeda Pharmaceuticals U.S.A., Inc.$24
- plus $76 from 4 others
What the payments were for
- Food & beverage$331100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 1 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $68 |
| Lilly USA, LLC | 2 | $36 |
| Johnson & Johnson | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| AstraZeneca | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Amgen | 1 | $20 |
| GSK | 1 | $14 |
How this compares
$331 in reported general payments places this provider in the 50th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 35 | $35,962 |
| JanuviaSitagliptin Phosphate | 12 | $20,028 |
| OzempicSemaglutide | 11 | $13,852 |
| Sucralfate | 13 | $1,654 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,222 |
| Atorvastatin Calcium | 135 | $889 |
| Losartan Potassium | 91 | $717 |
| Rosuvastatin Calcium | 67 | $700 |
| Levothyroxine Sodium | 63 | $658 |
| Gabapentin | 46 | $599 |
| Famotidine | 71 | $558 |
| Lisinopril | 73 | $534 |
| Metformin Hcl | 106 | $533 |
| Omeprazole | 49 | $458 |
| Amlodipine Besylate | 102 | $442 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Pembroke Pines
- Manuel GonzalezPembroke Pines$37K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.